DEFINIUM THERAPEUTICS INC (DFTX) Stock Fundamental Analysis

NASDAQ:DFTX • CA24477V1058

16.9 USD
+1.15 (+7.3%)
At close: Feb 17, 2026
16.91 USD
+0.01 (+0.06%)
After Hours: 2/17/2026, 8:09:53 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, DFTX scores 2 out of 10 in our fundamental rating. DFTX was compared to 191 industry peers in the Pharmaceuticals industry. DFTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DFTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • DFTX had negative earnings in the past year.
  • DFTX had a negative operating cash flow in the past year.
  • DFTX had negative earnings in each of the past 5 years.
  • DFTX had a negative operating cash flow in each of the past 5 years.
DFTX Yearly Net Income VS EBIT VS OCF VS FCFDFTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -70.95%, DFTX is doing worse than 71.73% of the companies in the same industry.
  • DFTX's Return On Equity of -128.72% is on the low side compared to the rest of the industry. DFTX is outperformed by 67.02% of its industry peers.
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROIC N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
DFTX Yearly ROA, ROE, ROICDFTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • DFTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DFTX Yearly Profit, Operating, Gross MarginsDFTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • DFTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DFTX has been increased compared to 5 years ago.
  • The debt/assets ratio for DFTX has been reduced compared to a year ago.
DFTX Yearly Shares OutstandingDFTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
DFTX Yearly Total Debt VS Total AssetsDFTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 4.27 indicates that DFTX is not in any danger for bankruptcy at the moment.
  • DFTX has a better Altman-Z score (4.27) than 72.77% of its industry peers.
  • DFTX has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of DFTX (0.31) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 4.27
ROIC/WACCN/A
WACCN/A
DFTX Yearly LT Debt VS Equity VS FCFDFTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • DFTX has a Current Ratio of 3.30. This indicates that DFTX is financially healthy and has no problem in meeting its short term obligations.
  • DFTX's Current ratio of 3.30 is in line compared to the rest of the industry. DFTX outperforms 53.93% of its industry peers.
  • DFTX has a Quick Ratio of 3.30. This indicates that DFTX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of DFTX (3.30) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 3.3
DFTX Yearly Current Assets VS Current LiabilitesDFTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 13.27% over the past year.
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, DFTX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.08% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.29%
EPS Next 2Y4.11%
EPS Next 3Y5.48%
EPS Next 5Y20.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DFTX Yearly Revenue VS EstimatesDFTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
DFTX Yearly EPS VS EstimatesDFTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • DFTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year DFTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DFTX Price Earnings VS Forward Price EarningsDFTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DFTX Per share dataDFTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.11%
EPS Next 3Y5.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • DFTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DEFINIUM THERAPEUTICS INC

NASDAQ:DFTX (2/17/2026, 8:09:53 PM)

After market: 16.91 +0.01 (+0.06%)

16.9

+1.15 (+7.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-05
Inst Owners41.21%
Inst Owner ChangeN/A
Ins Owners0.78%
Ins Owner Change36.66%
Market Cap1.66B
Revenue(TTM)N/A
Net Income(TTM)-168.10M
Analysts85
Price Target32.17 (90.36%)
Short Float %18.23%
Short Ratio7.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.53%
Min EPS beat(2)-52.55%
Max EPS beat(2)-34.51%
EPS beat(4)1
Avg EPS beat(4)-23.85%
Min EPS beat(4)-52.55%
Max EPS beat(4)27.56%
EPS beat(8)3
Avg EPS beat(8)-25.48%
EPS beat(12)5
Avg EPS beat(12)-13.29%
EPS beat(16)8
Avg EPS beat(16)-7.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)2.15%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.05%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.75
P/tB 15.04
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.33
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.95%
ROE -128.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 3.3
Altman-Z 4.27
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.89%
EPS Next Y-1.29%
EPS Next 2Y4.11%
EPS Next 3Y5.48%
EPS Next 5Y20.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.13%
EBIT Next 3Y-20.36%
EBIT Next 5Y19.82%
FCF growth 1Y-101.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.12%
OCF growth 3YN/A
OCF growth 5YN/A

DEFINIUM THERAPEUTICS INC / DFTX FAQ

Can you provide the ChartMill fundamental rating for DEFINIUM THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to DFTX.


What is the valuation status of DEFINIUM THERAPEUTICS INC (DFTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to DEFINIUM THERAPEUTICS INC (DFTX). This can be considered as Overvalued.


How profitable is DEFINIUM THERAPEUTICS INC (DFTX) stock?

DEFINIUM THERAPEUTICS INC (DFTX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for DEFINIUM THERAPEUTICS INC?

The Earnings per Share (EPS) of DEFINIUM THERAPEUTICS INC (DFTX) is expected to decline by -1.29% in the next year.